Rid, Annette
Annette Rid
VIAF ID: 623145857038722920992 (Personal)
Permalink: http://viaf.org/viaf/623145857038722920992
Preferred Forms
- 100 0 _ ‡a Annette Rid
- 100 1 _ ‡a Rid, Annette (sparse)
- 100 1 _ ‡a Rid, Annette
- 100 1 _ ‡a Rid, Annette
- 100 1 _ ‡a Rid, Annette
- 100 1 _ ‡a Rid, Annette
-
-
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
The 2008 Declaration of Helsinki - first among equals in research ethics? | |
Addressing exploitation of poor clinical trial participants in North America and the European Union. | |
Affordability and Non-Perfectionism in Moral Action | |
Can informed consent to research be adapted to risk? | |
The Challenge of Selecting Participants Fairly in High-Demand Clinical Trials | |
Challenges for the new Cancer Drugs Fund. | |
Choices in vaccine trial design in epidemics of emerging infections | |
Determination of Death: A Discussion on Responsible Scholarship, Clinical Practices, and Public Engagement. | |
Disclosure of incidental findings from next-generation sequencing in pediatric genomic research | |
Do Patients Want their Families or their Doctors to Make Treatment Decisions in the Event of Incapacity, and Why? | |
Ethical considerations of experimental interventions in the Ebola outbreak | |
Ethical Rationale for the Ebola "Ring Vaccination" Trial Design | |
Evaluating the risks of clinical research: direct comparative analysis | |
A framework for risk-benefit evaluations in biomedical research. | |
Genetic research on biospecimens poses minimal risk | |
The goals of research during an epidemic | |
How should we regulate risk in biomedical research? An ethical analysis of recent policy proposals and initiatives | |
The importance of being NICE. | |
Is the concept of clinical equipoise still relevant to research? | |
Judging the social value of controlled human infection studies | |
Justice in action? Introduction to the mini symposium on Norman Daniels' Just health: meeting health needs fairly. | |
Kommentar I zum Fall: „Heimlicher Transfer von HIV-Medikamenten nach Afrika“ | |
National Institute for Health and Care Excellence, social values and healthcare priority setting | |
Note of clarification concerning our article: controversies in the determination of death: perspectives from Switzerland | |
Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy? | |
Placebo use in vaccine trials: recommendations of a WHO expert panel | |
The potential exploitation of research participants in high income countries who lack access to health care | |
Prisoners as research participants: current practice and attitudes in the UK. | |
A proposal and prototype for a Research Risk Repository to improve the protection of research participants | |
Public participation in decision-making on the coverage of new antivirals for hepatitis C. | |
Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies | |
Regulating international clinical research: an ethical framework for policy-makers | |
Research led by participants: a new social contract for a new kind of research | |
Risks of phase I research with healthy participants: A systematic review | |
Setting risk thresholds in biomedical research: lessons from the debate about minimal risk | |
Standards of practice in empirical bioethics research: towards a consensus | |
Substantiating the Social Value Requirement for Research: An Introduction. | |
Systematic review: the effect on surrogates of making treatment decisions for others | |
Tackling anti-microbial resistance: ethical framework for rational antibiotic use. | |
Towards Equity in Health: Researchers Take Stock | |
Universal health coverage, priority setting, and the human right to health. | |
What is enough? : sufficiency, justice, and health | |
When is research socially valuable? Lessons from the Bucharest Early Intervention Project: commentary on a case study in the ethics of mental health research | |
Why should high-income countries help combat Ebola? | |
Will a patient preference predictor improve treatment decision making for incapacitated patients? |